secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001193125-23-274068
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Wave Life Sciences Q3 net income $7.3M; initiates first RNA editing clinical program, WVE-006
--------------------------------------------------------------------------------

- Net income of $7.3M vs net loss of $39.0M YoY; revenue increase driven by $48.9M in collaboration milestones.
- Cash $139.9M as of Sep 30, plus $7M milestone received in 4Q; runway into 2025.
- Initiated RestorAATion clinical program for WVE-006 (RNA editing for AATD); dosing in 4Q 2023, proof-of-mechanism data in 2024.
- Enrolled 30mg multi-dose cohort of SELECT-HD for WVE-003; data in 2Q 2024 to enable Takeda opt-in.
- Preclinical INHBE siRNA data for obesity; clinical candidate selection in 4Q 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312523274068/0001193125-23-274068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312523274068/d243880d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-274068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer